The correlation between lncRNA NEAT1 and serum hepcidin in the peripheral blood of non-alcoholic fatty liver disease patients

Wenyong Zhou1, Kongjun Qiu2

1Department of General Surgery, Cangzhou Central Hospital, Cangzhou 061001, Hebei, China; 2Operating Room, Cangzhou People’s Hospital, Cangzhou 061000, Hebei, China

Received April 7, 2021; Accepted August 13, 2021; Epub April 15, 2022; Published April 30, 2022

Abstract: Objectives: To explore and analyze the correlation between lncRNA NEAT1 and serum hepcidin (HEPC) in the peripheral blood of non-alcoholic fatty liver disease patients. Methods: 119 patients, confirmed to have non-alcoholic fatty liver disease (NAFLD) and admitted to our hospital from January 2017 to June 2019, were enrolled in the NAFLD group, and 100 healthy subjects during the same period were enrolled in the control group. We recorded the two groups’ general information and routine laboratory examination results and performed correlation analyses on the lncRNA NEAT1 expressions in their peripheral blood mononuclear cells (PBMCs) and HEPC. Results: The BMI, the waist circumferences, and the ALT, GGT, TC, and TG levels in the NAFLD group were critically higher than they were in the control group (P<0.05). The relative expressions of lncRNA NEAT1 in the PBMCs of the NAFLD group were remarkably higher than they were in the control group (P<0.05). The HEPC levels in the NAFLD group were significantly higher than they were in the control group (P<0.05). The lncRNA NEAT1 expressions in the peripheral blood had a positive correlation with the ALT, GGT, TC, and TG levels (P<0.05). The HEPC levels were positively correlated with the ALT, GGT, TC, and TG levels in the NAFLD patients (P<0.05), and the lncRNA NEAT1 expressions in the peripheral blood had a positive correlation with HEPC (P<0.05). We used ROC curves to analyze the diagnostic value of lncRNA NEAT1 in the peripheral blood to NAFLD, and the area under the curve was 0.822 (95% confidence interval of overall probability: 0.612~0.921). The sensitivity was 86.47%, and the specificity was 82.03%. Conclusion: lncRNA NEAT1 is abnormally overexpressed in the PBMCs of patients with NAFLD. The regulatory effect of lncRNA NEAT1 on NAFLD may be related to the mechanism of HEPC, which is expected to be a potential biological indicator for the prevention and treatment of NAFLD.

Keywords: Non-alcoholic fatty liver (NAFLD), peripheral blood, lncRNA NEAT1, serum hepcidin (HEPC), correlation

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a metabolic stress hepatic injury represented by hepatocyte steatosis and viral inflammation of liver. NAFLD includes simple hepatic steatosis, non-alcoholic steatohepatitis, and eventually cirrhosis and even hepatocellular carcinoma [1]. Long non-coding RNA (IncRNA) is a type of non-coding RNA with a transcription length over 200 nt. Current studies suggest that IncRNA can target multiple genes such as transcription factors, activators and suppressors, regulate the transcription and expression of genes, and participate in the occurrence and progression of a variety of diseases [2, 3]. In addition, IncRNA can participate in the regulation of genes and the synthesis of proteins in cells in a variety of ways, affecting the metabolism of intracellular substances, and then participating in the occurrence and progression of NAFLD [5]. IncRNA NEAT1, a member of the IncRNA family, is abnormally expressed in a variety of tumors. Studies suggest that IncRNA NEAT1 is involved in hepatocyte injury [6]. Also, iron metabolism has been a research focus in the pathogenesis of NAFLD, the mechanism of which is yet to be fully clarified. Some scholars have proposed that iron metabolism affects the disease progression of NAFLD, and it may be related to factors such as lipid peroxidation, oxidative stress, and insulin resistance [7].
Currently, the influence mechanism of IncRNA on NAFLD has not been clarified, and we speculate that IncRNA-NEAT1 affects the disease progression through the regulation of iron metabolism. In this study, the correlation between the peripheral blood IncRNA-NEAT1 levels in patients with NAFLD and the hepcidin (HEPC) levels and the TLR4/NF-κB pathway were investigated and analyzed. The report is as follows.

Materials and methods

Clinical data

In this retrospective study, 119 subjects that confirmed to have non-alcoholic fatty liver disease (NAFLD) and admitted to our hospital from January 2017 to June 2019 were enrolled in the NAFLD group, and 100 healthy subjects who visited our hospital during the same period were enrolled in the control group. The study was authorized by the hospital’s ethics committee.

Inclusion and exclusion criteria

Inclusion criteria: (1) The patient diagnoses were in line with the diagnostic criteria in the Guidelines for the Prevention and Treatment of Non-alcoholic Fatty Liver Disease (2018 update) [8]; (2) Patients ≥18 years old; and (3) Both groups of subjects voluntarily signed the informed consent forms.

Exclusion criteria: (1) Subjects with viral hepatitis, liver tumors or liver cirrhosis; (2) Patients with type 2 diabetes; (3) Patients with acute or chronic inflammation; (4) Patients with other diseases, such as tumors, immune system diseases, tuberculosis, hematological diseases, chronic atrophic gastritis, etc.; (5) Patient who had used immunomodulators within one month before their enrollment; (6) Patients with hepatolenticular degeneration; and (7) Patients who had consumed large quantities of alcohol.

Methods

General information: The two groups’ general data, including their genders, ages, body weights, waist circumferences, hip circumferences, blood pressure, etc., were recorded. At the same time, we performed routine laboratory tests on the patients, including determining their aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyltransferase (GGT), alkaline phosphatase (ALP), total cholesterol (TC), triacylglycerol (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels.

Reagents and equipment: Ficoll lymphocyte separation solution (Sigma, USA); Trizol reagent (Invitrogen, USA); Prime Script™ RT reagent Kit with gDNA Eraser and SYBR® Premix Ex Taq™ (Dalian TaKaRa, Japan); Human Hepcidin Quantikine ELISA Kit (American R&D, DHP250); Spectrophotometer (Bio-Rad Company, USA); and 7600 Fluorescence quantitative PCR (Applied Biosystems).

Measuring the IncRNA-NEAT1 levels in the peripheral blood: Early morning fasting venous blood (5 ml) from the two groups of subjects was drawn and mixed well in heparin sodium anticoagulation tubes. PBMC was extracted using a Ficoll lymphocyte separation solution. The total RNA of PBMC was extracted according to instructions of the Trizol reagent, and its concentration and purity were measured using a spectrophotometer. After passing the test, the total RNA was frozen at -80°C. The IncRNA NEAT1 expressions were analyzed by taking GAPDH as internal reference gene. Prime ScriptTM RT reagent Kits with a gDNA Eraser were used to reverse-transcribe the RNA into cDNA. The RT-PCR quantification was conducted using the SYBR method, and the measurement routines and reaction requirements were carried out in accordance with the kit’s instructions. The primer sequences were synthesized by the Shanghai Shenggong Biological Engineering Co., Ltd. The forward primer of IncRNA NEAT1 was 5’-CTTCCTCCCTTAACTTATCCATTC-3’ and the reverse primer was 5’-CTCTCCCTTACATCCATCAC-3’. The reaction system: pre-denaturation at 95°C for 10 min, 95°C for 15 s, 60°C for 1 min and 72°C for 30 s, with a total of 40 cycles. All the samples were made with 3 holes, and the relative expressions of IncRNA NEAT1 were calculated using the 2^ΔΔCT method.

Measuring the HEPC

Early morning fasting venous blood was drawn from the two groups of subjects, centrifuged at 3000 r/min for 10 min to take the supernatant. ELISA was used to measure the HEPC levels in both groups strictly according to the instructions.
In lncRNA NEAT1 expressions in nonalcoholic fatty liver disease patients

Statistical analysis

SPSS 22.0 was used to examine the collected data. The measurement data were presented as (X±s) and compared using t tests between the two groups. The enumeration data were recorded as percentages and compared using X² tests. Pearson correlation coefficients were used for the correlation analyses, with P<0.05 considered to be a statistically significant difference.

The lncRNA NEAT1 expressions in the two groups’ peripheral blood

The relative lncRNA NEAT1 expressions in the PBMC of the NAFLD group were notably higher than they were in the control group [(2.974±0.642) vs. (1.240±0.339), P<0.05], as shown in Figure 1.

Comparison of the two groups’ serum HEPC levels

The serum HEPC levels in the NAFLD group were critically higher than they were in the control group [(98.84±13.42) vs. (61.08±6.45), P<0.05], as elaborated in Figure 2.

Analysis of the correlation between the serological indicators and the lncRNA NEAT1 expressions

The lncRNA NEAT1 expressions in the peripheral blood had a remarkably positive connection with the ALT, GGT, TC, and TG levels in the NAFLD group (r=0.467, 0.389, 0.399, 0.344, P<0.05), as shown in Figure 3.

Analysis of the correlation between the serological indicators and the HEPC levels

There was a significant positive correlation between serum HEPC levels and the ALT, GGT, TC, and TG levels in the patients with NAFLD (r=0.457, 0.512, 0.506, 0.391, P<0.05), as indicated in Figure 4.
IncRNA NEAT1 expressions in nonalcoholic fatty liver disease patients

For obese patients, the presence of NAFLD may indicate "malignant obesity", with a marked increase in the probability of diabetes, hypertension, dyslipidemia, coronary heart disease, and stroke [11, 12]. However, the pathogenesis of NAFLD has not yet been completely clarified, and there is a lack of effective drug treatment in clinical practice. Therefore, it is urgent to clarify the pathogenesis of NAFLD and to seek effective precautions and treatments.

IncRNA is a group of RNA transcripts with a length of over 200 nt and no protein coding function. It has been found that IncRNA participates in many biological processes of liver cells and plays a crucial role in a variety of liver pathological processes. IncRNA is related to endoplasmic reticulum function, mitochondria, and energy metabolism [13, 14]. IncRNA-H19 directly regulates the miR130a/PPARγ axis to promote the synthesis of NAFLD fat [15]. The liver fibrosis and hepatocellular apoptosis in NAFLD rats can be promoted by inhibiting the expression of lncRNA HULC in the MAPK signaling pathway. IncRNA MIRT2 sponges miR-34a-5p, thereby upregulating the expression of USP10 and inhibiting liver steatosis [17]. As an endogenous and competitive RNA, lncRNA MEG3 regulates hepatic adipogenesis by competitively binding miR-21 to low-density lipoprotein receptor-related protein-6 (LRP6) [18]. The above study results suggest that lncRNA plays an essential role in NAFLD. It shows that the relative expression of lncRNA NEAT1 in the PBMC of the NAFLD group was notably higher than it was in the control group. The results are similar to those reported by other researchers [19, 20], suggesting that there is abnormal regulation of lncRNA NEAT1 expression in the process of NAFLD disease. In addition, the IncRNA NEAT1 expressions in the peripheral blood of NAFLD patients is remarkably positively correlated with the ALT, GGT, TC, and TG levels, suggesting that the regulation of IncRNA NEAT1 expression in NAFLD subjects is related to liver function and lipid metabolism.

The small intestine is the main organ for iron absorption, and the liver is the main site for iron storage. Since most people consume far more iron in their diet than the body needs, the liver, as the core organ for iron metabolism, is likely to cause iron deposition in the liver after being damaged [21, 22]. There are a variety of iron regulative proteins in human body.
recent years, researchers have found a new iron regulative protein, HEPC. Researchers have found that HEPC plays a vital function in the process of iron metabolism, especially in some chronic anemia diseases [23]. HEPC is a small molecule antimicrobial peptide secreted by the liver, and its target cells include hepatocytes, intestinal epithelial cells, and macrophages. HEPC can be bonded to the iron transporter-1 on such cell membranes to inhibit the transport of iron by transporters, thereby promoting the deposition of iron in cells [24]. The results of recent animal experiments show that iron and fat accumulated in liver cells can synergistically induce the injury and the death of hepatocytes [25]. This study’s results show that the serum HEPC in the NAFLD group was critically higher than it was in the control group. The results, similar to those reported by other researchers [26], suggest that there is abnormal iron metabolism in the process of NAFLD disease. In addition, the serum HEPC level in the NAFLD patients was notably positively correlated with the ALT, GGT, TC, and TG levels, indicating that the HEPC levels in NAFLD patients are related to their liver function and lipid metabolism.

The IncRNA NEAT1 expression in the peripheral blood of NAFLD subjects was significantly positively correlated with the HEPC levels, suggesting that the regulative mechanism of IncRNA NEAT1 on NAFLD disease may be related to the regulation of iron metabolism in the human body. Using ROC curves to analyze the diagnostic value of IncRNA NEAT1 in the peripheral blood to NAFLD, the area under the curve was 0.822 (95% confidence interval of overall probability: 0.612~0.921), the sensitivity and the specificity were 86.47% and 82.03% respectively. This suggests that IncRNA NEAT1 may be a possible biological target for the prevention and treatment of NAFLD. The results of this study are similar to those reported by other researchers [27], namely that IncRNA NEAT1 plays a key role in the occurrence and progression of NAFLD disease. In addition, the regulation of this disease may be connected to the regulation of iron metabolism in the body.
In other words, a patient’s lipid metabolism is further affected through the regulation of iron metabolism, so the further progression of the disease is promoted or blocked.

However, there are still deficiencies in this study, including the limited sample size as well as the lack of an in-depth analysis of the specific pathway between IncRNA NEAT1 and iron metabolism. Therefore, it is necessary to expand the sample size and analyze the specific mechanism of IncRNA NEAT1 regulation in subsequent studies in order to make better progress in clinical work.

Disclosure of conflict of interest

None.

Address correspondence to: Wenyong Zhou, Department of General Surgery, Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou 061001, Hebei, China. Tel: +86-15903175117; E-mail: zhouwenyong1101@163.com

References

[10] Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D and Grønbæk H. The role of macrophages in...
IncRNA NEAT1 expressions in nonalcoholic fatty liver disease patients


[18] Polyzos SA, Kountouras J and Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism 2019; 92: 82-97.


